Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany

Abstract

Background The Atopic Dermatitis (AD) TREATgermany registry was initiated by the German Society for Dermatology (DDG) in 2011 to evaluate the 'real-life' situation of health care for patients with AD.

Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREAT germany

“…Between June 2016 and January 2019, 612 patients (mean age 42·6 years, 38·2% female) were enrolled by 32 recruitment sites centres (16 hospital outpatient departments and 16 registered dermatological offices) . Since December 2017, when dupilumab was launched in Germany, 200 registry patients have received a new systemic therapy within routine care.…”

“…D ear E ditor , The German atopic eczema registry TREATgermany is a noninterventional multicentre patient cohort study for adult patients with current moderate‐to‐severe disease activity or current or previous anti‐inflammatory systemic treatment . Dupilumab was demonstrated to be an effective treatment for patients with moderate‐to‐severe atopic eczema in clinical trials .…”

Precision medicine reaching out to the patients in allergology – a German-Japanese workshop report

“…Meanwhile, a number of proteins involved in the establishment of the skin barrier are known to show mutations in subgroups of patients with AD [ 59 ]. The immune system is mainly polarized towards a type 2 cytokine pattern which offers multiple targets for innovative treatments – dupilumab, a blocking antibody of the IL-4 Rα chain is the first substance approved in 2017, and real-world data coming from the German Registry of AD (“TREATgermany”) nicely confirm efficacy data from placebo-controlled studies [ 60 , 61 ]. A couple of new developments will follow (e.g., anti-IL-13 antibodies, anti-IL-31-receptor antibodies and Janus kinase (JAK) inhibitors acting on the intracellular sites of cytokine receptors) [ 62 ].…”

Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis

“…To gain deeper insights into the potential role of NK cells in the regulation of type 2 inflammation, we conducted sensitive immunofluorescence staining of NK cells and an in-depth characterization of NK-cell-related expression signatures including in silico cytometry in transcriptome data on lesional and nonlesional skin biopsies from patients of the TREATgermany AD registry 13 before and 3 months after systemic treatment as well as in healthy controls. 14 For detailed Methods, please see the Methods section in this article's Online Repository at www.jacionline.org.…”